JW-004

N/A

Report date: 2025/05/30 17:22:48

Base Information

Drug NameJW-004
Drug Alias NameJW004JW-004
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionGlypican-3 modulatorsT lymphocyte replacements
TargetsGlypican-3
Therapy Area/IndicationsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesJw Therapeutics (Shanghai) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJw Therapeutics (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A